Skip to main content
Erschienen in: Intensive Care Medicine 1/2004

01.01.2004 | Review

Dosing of medications in morbidly obese patients in the intensive care unit setting

verfasst von: Brian L. Erstad

Erschienen in: Intensive Care Medicine | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To derive recommendations for the dosing of commonly used medications in the morbidly obese patient in the ICU.

Data sources

Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references.

Study selection

All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients.

Data extraction

The emphasis was on studies involving morbidly obese patients but, in the absence of such data, investigations involving lesser forms of obesity were extracted.

Data synthesis

There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obese patient in the ICU, although recommendations were provided based on the available information.

Conclusions

There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez AL, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez AL, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMed
2.
Zurück zum Zitat Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25:1289–1297CrossRefPubMed Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25:1289–1297CrossRefPubMed
3.
Zurück zum Zitat Zarowitz BJ, Petitta A, Rudis MI, Horst HM, Hyzy R (1996) Bar code documentation of pharmacotherapy services in intensive care units. Pharmacotherapy 16:261–266PubMed Zarowitz BJ, Petitta A, Rudis MI, Horst HM, Hyzy R (1996) Bar code documentation of pharmacotherapy services in intensive care units. Pharmacotherapy 16:261–266PubMed
4.
Zurück zum Zitat Roubenoff R, Kehayias JJ (1991) The meaning and measurement of lean body mass. Nutrition Rev 49:163–175CrossRef Roubenoff R, Kehayias JJ (1991) The meaning and measurement of lean body mass. Nutrition Rev 49:163–175CrossRef
5.
Zurück zum Zitat Devine BJ (1974) Case number 25: gentamicin therapy. Drug Intell Clin Pharm 8:650–655CrossRef Devine BJ (1974) Case number 25: gentamicin therapy. Drug Intell Clin Pharm 8:650–655CrossRef
6.
Zurück zum Zitat Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Arlet M (1983) Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 40:1016–1019PubMed Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Arlet M (1983) Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 40:1016–1019PubMed
7.
Zurück zum Zitat World Health Organization (1998) Obesity: preventing and managing the global epidemic, report of a WHO consultation on obesity. Geneva, June 3–5 World Health Organization (1998) Obesity: preventing and managing the global epidemic, report of a WHO consultation on obesity. Geneva, June 3–5
8.
Zurück zum Zitat National Heart, Lung and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases (September 1998) Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH Publication No. 98–4083 National Heart, Lung and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases (September 1998) Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH Publication No. 98–4083
9.
Zurück zum Zitat Rand CSW, Kuldau JM, Yost RL (1999) Obesity and post-operative pain. J Psychosom Res 29:43–48CrossRef Rand CSW, Kuldau JM, Yost RL (1999) Obesity and post-operative pain. J Psychosom Res 29:43–48CrossRef
10.
Zurück zum Zitat Bennett R, Baterhorst R, Graves DA, Foster TS, Griffen WO, Wright BD (1982) Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy 2:50–53CrossRefPubMed Bennett R, Baterhorst R, Graves DA, Foster TS, Griffen WO, Wright BD (1982) Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy 2:50–53CrossRefPubMed
11.
12.
Zurück zum Zitat James WPT (1976) Research on obesity. Her Majesty’s Stationary Office, London James WPT (1976) Research on obesity. Her Majesty’s Stationary Office, London
13.
Zurück zum Zitat Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT (1998) Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 89:562–573CrossRefPubMed Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT (1998) Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 89:562–573CrossRefPubMed
14.
Zurück zum Zitat Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivias S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 119:874–881CrossRefPubMed Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivias S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 119:874–881CrossRefPubMed
15.
Zurück zum Zitat Ellison MJ, Sawyer WT, Mills TC (1989) Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 8:65–68PubMed Ellison MJ, Sawyer WT, Mills TC (1989) Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 8:65–68PubMed
16.
Zurück zum Zitat Duplaga BA, Rivers CW, Nutescu E (2001) Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21:218–234CrossRefPubMed Duplaga BA, Rivers CW, Nutescu E (2001) Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21:218–234CrossRefPubMed
17.
Zurück zum Zitat Yee JYV, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 56:293–297CrossRefPubMed Yee JYV, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 56:293–297CrossRefPubMed
18.
Zurück zum Zitat Wilson SJ, Wilbur K, Burton E, Anderson DR (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31:42–48PubMed Wilson SJ, Wilbur K, Burton E, Anderson DR (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31:42–48PubMed
19.
Zurück zum Zitat Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK (1998) Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 91:137–142CrossRefPubMed Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK (1998) Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 91:137–142CrossRefPubMed
20.
Zurück zum Zitat Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW, Hua TA, Gastonguay M (2001) Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39:431–446PubMed Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW, Hua TA, Gastonguay M (2001) Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39:431–446PubMed
21.
Zurück zum Zitat Priglinger U, Karth GD, Geppert A, Joukhadour C, Berger R, Hulsman M, Pabinger I, Heinz G (2002) Prophylactic anticoagulation with low dose enoxaparin—is the subcutaneous route appropriate in the critically ill? Crit Care Med 29 (suppl):A97 Priglinger U, Karth GD, Geppert A, Joukhadour C, Berger R, Hulsman M, Pabinger I, Heinz G (2002) Prophylactic anticoagulation with low dose enoxaparin—is the subcutaneous route appropriate in the critically ill? Crit Care Med 29 (suppl):A97
22.
Zurück zum Zitat Abernethy DR, Greenblatt DJ (1985) Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 42:468–471CrossRefPubMed Abernethy DR, Greenblatt DJ (1985) Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 42:468–471CrossRefPubMed
23.
Zurück zum Zitat Houghton GW, Richens A, Leighton M (1975) Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 2:251–256CrossRefPubMedPubMedCentral Houghton GW, Richens A, Leighton M (1975) Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 2:251–256CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Traynor AM, Nafziger AN, Bertino JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545–548CrossRefPubMedPubMedCentral Traynor AM, Nafziger AN, Bertino JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545–548CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Blouin RA, Mann HJ, Griffen WO, Bauer LA, Record KE (1979) Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 26:508–512CrossRefPubMed Blouin RA, Mann HJ, Griffen WO, Bauer LA, Record KE (1979) Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 26:508–512CrossRefPubMed
26.
Zurück zum Zitat Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM (1980) Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37:519–522PubMed Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM (1980) Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37:519–522PubMed
27.
Zurück zum Zitat Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643–647CrossRefPubMed Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643–647CrossRefPubMed
28.
Zurück zum Zitat Buchholz U, Richards C, Murthy R, Arduino M, Pon D, Schwartz W, Fontanilla E, Pegues C, Boghossian N, Peterson C, Kool J, Mascola L, Jarvis WR (2000) Pyrogenic reactions associated with single daily dosing of intravenous gentamicin. Infect Control Hosp Epidemiol 21:771–774CrossRefPubMed Buchholz U, Richards C, Murthy R, Arduino M, Pon D, Schwartz W, Fontanilla E, Pegues C, Boghossian N, Peterson C, Kool J, Mascola L, Jarvis WR (2000) Pyrogenic reactions associated with single daily dosing of intravenous gentamicin. Infect Control Hosp Epidemiol 21:771–774CrossRefPubMed
29.
Zurück zum Zitat Kampmann JP, Klein H, Lumholtz B, Hansen JEM (1984) Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 9:168–176CrossRefPubMed Kampmann JP, Klein H, Lumholtz B, Hansen JEM (1984) Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 9:168–176CrossRefPubMed
30.
Zurück zum Zitat Yost RL, Deredorf H (1986) Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 8:189–194CrossRefPubMed Yost RL, Deredorf H (1986) Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 8:189–194CrossRefPubMed
31.
Zurück zum Zitat Mann HJ, Buchwald H (1986) Cefamandole distribution in serum, adipose tissue and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 20:869–873CrossRefPubMed Mann HJ, Buchwald H (1986) Cefamandole distribution in serum, adipose tissue and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 20:869–873CrossRefPubMed
32.
Zurück zum Zitat Pories WJ, van Rij AM, Burlingham BT, Fulghum S, Meelbeim D (1981) Prophylactic cefazolin in gastric bypass surgery. Surgery 90:426–432PubMed Pories WJ, van Rij AM, Burlingham BT, Fulghum S, Meelbeim D (1981) Prophylactic cefazolin in gastric bypass surgery. Surgery 90:426–432PubMed
33.
Zurück zum Zitat Forse RA, Karam B, MacLean LD, Christou NV (1989) Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106:750–757PubMed Forse RA, Karam B, MacLean LD, Christou NV (1989) Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106:750–757PubMed
34.
Zurück zum Zitat Allard S, Kinzig M, Boivin G, Sorgel F, LaBel M (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368–373CrossRefPubMed Allard S, Kinzig M, Boivin G, Sorgel F, LaBel M (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368–373CrossRefPubMed
35.
Zurück zum Zitat Caldwell JB (1994) Intravenous ciprofloxacin dosing in a morbidly obese patient (letter). Ann Pharmacother 28:806CrossRefPubMed Caldwell JB (1994) Intravenous ciprofloxacin dosing in a morbidly obese patient (letter). Ann Pharmacother 28:806CrossRefPubMed
36.
Zurück zum Zitat Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575–580CrossRefPubMedPubMedCentral Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575–580CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621–625CrossRefPubMed Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621–625CrossRefPubMed
38.
Zurück zum Zitat Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics and clinical use. Ann Pharmacother 30:637–643CrossRefPubMed Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics and clinical use. Ann Pharmacother 30:637–643CrossRefPubMed
39.
Zurück zum Zitat Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F-50FCrossRefPubMed Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F-50FCrossRefPubMed
40.
Zurück zum Zitat Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102:740–744CrossRefPubMed Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102:740–744CrossRefPubMed
41.
Zurück zum Zitat Abernethy DR, Greenblatt DJ (1984) Lidocaine disposition in obesity. Am J Cardiol 53:1183–1186CrossRefPubMed Abernethy DR, Greenblatt DJ (1984) Lidocaine disposition in obesity. Am J Cardiol 53:1183–1186CrossRefPubMed
42.
Zurück zum Zitat Christoff PB, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17:516–522CrossRefPubMed Christoff PB, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17:516–522CrossRefPubMed
43.
Zurück zum Zitat Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, Snoeck E (1997) Pharmacokinetics of β-adrenoreceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563–570CrossRefPubMedPubMedCentral Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, Snoeck E (1997) Pharmacokinetics of β-adrenoreceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563–570CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J (1987) Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27:874–879CrossRefPubMed Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J (1987) Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27:874–879CrossRefPubMed
45.
Zurück zum Zitat Abernethy DR, Schwartz JB (1988) Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 11:209–215CrossRefPubMed Abernethy DR, Schwartz JB (1988) Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 11:209–215CrossRefPubMed
46.
Zurück zum Zitat Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. DICP Ann Pharmacother 24:1040–1043 Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. DICP Ann Pharmacother 24:1040–1043
47.
Zurück zum Zitat Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91–94PubMed Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91–94PubMed
48.
Zurück zum Zitat Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall LF, Perot PL, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JE, Winn HR (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 322:1405–1411CrossRefPubMed Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall LF, Perot PL, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JE, Winn HR (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 322:1405–1411CrossRefPubMed
49.
Zurück zum Zitat Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VKH, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597–1604CrossRefPubMed Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VKH, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597–1604CrossRefPubMed
50.
Zurück zum Zitat Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ (1991) Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 49:536–549CrossRefPubMed Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ (1991) Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 49:536–549CrossRefPubMed
51.
Zurück zum Zitat Varin F, Ducharme J, Theoret Y, Besner YG, Bevan DR, Donati F (1990) Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 48:18–25CrossRefPubMed Varin F, Ducharme J, Theoret Y, Besner YG, Bevan DR, Donati F (1990) Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 48:18–25CrossRefPubMed
52.
Zurück zum Zitat Puhringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A (1999) Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 16:507–510CrossRefPubMed Puhringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A (1999) Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 16:507–510CrossRefPubMed
53.
Zurück zum Zitat Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J (1992) Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 74:515–518PubMed Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J (1992) Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 74:515–518PubMed
54.
Zurück zum Zitat Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23:438–444CrossRefPubMed Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23:438–444CrossRefPubMed
55.
Zurück zum Zitat Zahorska-Markiewicz B, Waluga M, Zielinski M, Klin M (1996) Pharmacokinetics of theophylline in obesity. Int J Clin Pharmacol Ther 34:393–395PubMed Zahorska-Markiewicz B, Waluga M, Zielinski M, Klin M (1996) Pharmacokinetics of theophylline in obesity. Int J Clin Pharmacol Ther 34:393–395PubMed
56.
Zurück zum Zitat Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1981) Alterations in drug distribution and clearance in obesity. J Pharmacol Exp Ther 217:681–685PubMed Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1981) Alterations in drug distribution and clearance in obesity. J Pharmacol Exp Ther 217:681–685PubMed
57.
Zurück zum Zitat Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI (1984) Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 61:27–35CrossRefPubMed Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI (1984) Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 61:27–35CrossRefPubMed
58.
Zurück zum Zitat Servin F, Farinotti R, Haberer JP, Desmonts JM (1993) Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology 78:657–665CrossRefPubMed Servin F, Farinotti R, Haberer JP, Desmonts JM (1993) Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology 78:657–665CrossRefPubMed
59.
Zurück zum Zitat Tsikouris JP, Tsikouris AP (2001) A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 21:207–217CrossRefPubMed Tsikouris JP, Tsikouris AP (2001) A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 21:207–217CrossRefPubMed
60.
Zurück zum Zitat The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587CrossRef The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587CrossRef
61.
Zurück zum Zitat Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017–1025CrossRefPubMed Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017–1025CrossRefPubMed
62.
Zurück zum Zitat MacGregor DA, Smith TE, Prielipp RC, Butterworth JF, James RL, Scuderi PE (2000) Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92:338–346CrossRefPubMed MacGregor DA, Smith TE, Prielipp RC, Butterworth JF, James RL, Scuderi PE (2000) Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92:338–346CrossRefPubMed
63.
Zurück zum Zitat Klem C, Dasta JF, Reilley TE, Flancbaum LJ (1994) Variability of dobutamine pharmacokinetics in unstable critically ill patients. Crit Care Med 22:1926–1932CrossRefPubMed Klem C, Dasta JF, Reilley TE, Flancbaum LJ (1994) Variability of dobutamine pharmacokinetics in unstable critically ill patients. Crit Care Med 22:1926–1932CrossRefPubMed
64.
Zurück zum Zitat Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children: inotropes and vasopressors. Clin Pharmacokinet 27:345–367CrossRefPubMed Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children: inotropes and vasopressors. Clin Pharmacokinet 27:345–367CrossRefPubMed
Metadaten
Titel
Dosing of medications in morbidly obese patients in the intensive care unit setting
verfasst von
Brian L. Erstad
Publikationsdatum
01.01.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 1/2004
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-003-2059-6

Weitere Artikel der Ausgabe 1/2004

Intensive Care Medicine 1/2004 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.